Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...

Like Kymera, I am not prepared to give up on the protein deg story yet, and although a poor set of data, or the exit of Sanofi from the KT-474 program could derail the company's share price ...

Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties, and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25 ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Sanofi has informed Kymera that it will advance KT-485, Kymera's drug candidate targeting IRAK4 for immuno-inflammatory diseases, into clinical studies and not proceed with KT-474.

Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi and announced a $250 million secondary offering.

Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical ...

Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.